Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

The current study identified prognostic factors in advanced melanoma for patients who experienced disease progression while receiving anti-PD-1, including lactate dehydrogenase, stage of disease, site of disease progression, tumor size, and mutation status.